Anebulo Pharmaceuticals, Inc.
NASDAQ:ANEB
1.5955 (USD) • At close January 14, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|
| Assets: | |||||
| Current Assets: | |||||
| Cash & Cash Equivalents
| 3.094 | 11.247 | 14.548 | 19.986 | 3.025 |
| Short Term Investments
| 0 | 0 | 0 | 0 | 0 |
| Cash and Short Term Investments
| 3.094 | 11.247 | 14.548 | 19.986 | 3.025 |
| Net Receivables
| 0 | 0 | 0 | 0 | 0.004 |
| Inventory
| 0 | 0 | 0 | 0 | -0 |
| Other Current Assets
| 0.414 | 0.423 | 1.031 | 1.668 | 0 |
| Total Current Assets
| 3.508 | 11.247 | 14.548 | 19.986 | 3.028 |
| Non-Current Assets: | |||||
| Property, Plant & Equipment, Net
| 0 | 0 | 0 | 0 | 0 |
| Goodwill
| 0 | 0 | 0 | 0 | 0 |
| Intangible Assets
| 0 | 0 | 0 | 0 | 0 |
| Goodwill and Intangible Assets
| 0 | 0 | 0 | 0 | 0 |
| Long Term Investments
| 0 | 0 | 0 | 0 | 0 |
| Tax Assets
| 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets
| 0.565 | 0 | 0 | 0 | 0 |
| Total Non-Current Assets
| 0.565 | 0 | 1.031 | 1.668 | 0 |
| Total Assets
| 4.073 | 11.67 | 15.579 | 21.653 | 3.028 |
| Liabilities & Equity: | |||||
| Current Liabilities: | |||||
| Account Payables
| 0.156 | 0.535 | 0.381 | 0.11 | 0 |
| Short Term Debt
| 0 | 0 | 0 | 0 | 0.201 |
| Tax Payables
| 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue
| 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities
| 0.104 | 0.534 | 0.132 | 0.132 | 0.023 |
| Total Current Liabilities
| 0.261 | 0.535 | 0.513 | 0.242 | 0.224 |
| Non-Current Liabilities: | |||||
| Long Term Debt
| 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue Non-Current
| 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities Non-Current
| 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities
| 0 | 0 | 0 | 0 | 0 |
| Total Non-Current Liabilities
| 0 | 0.534 | 0.381 | 0.132 | 2.976 |
| Total Liabilities
| 0.261 | 1.069 | 0.513 | 0.242 | 3.2 |
| Equity: | |||||
| Preferred Stock
| 0 | 0 | 0 | 21.653 | 2.976 |
| Common Stock
| 0.026 | 0.026 | 0.023 | 0.023 | 0.012 |
| Retained Earnings
| -65.404 | -57.202 | -45.47 | -38.644 | -0.183 |
| Accumulated Other Comprehensive Income/Loss
| 0 | 0 | 0 | -21.653 | -2.988 |
| Other Total Stockholders Equity
| 69.19 | 67.778 | 60.513 | 38.379 | 0.012 |
| Total Shareholders Equity
| 3.813 | 10.601 | 15.067 | 21.412 | -0.171 |
| Total Equity
| 3.813 | 10.601 | 15.067 | 21.412 | -0.171 |
| Total Liabilities & Shareholders Equity
| 4.073 | 11.67 | 15.579 | 21.653 | 3.028 |